Calsequestrin in Ventricular Arrhythmia and Sudden Death

Calsequestrin 治疗室性心律失常和猝死

基本信息

  • 批准号:
    7790765
  • 负责人:
  • 金额:
    $ 44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-04-15 至 2012-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cardiac calsequestrin (CASQ2), and its binding partners junctin and triadin-1 (TRDN), are key regulators of sarcoplasmic reticulum (SR) Ca2+ storage and release. In humans, CASQ2 mutations cause a syndrome of catecholaminergic polymorphic ventricular tachycardia and sudden cardiac death. To determine the mechanisms whereby CASQ2 mutations cause electrophysiologic instability but preserve contractile function, we have generated Casq2 null (Casq2-/-) mice. Our preliminary studies demonstrate that despite a lack of Casq2 protein, these mice maintain near normal SR Ca2+ storage, possibly as a result of an expansion of SR volume and drastic reductions in the Casq2 binding proteins triadin-1 and junctin. Casq2-/- mice phenocopy the human CASQ2- linked arrhythmias by developing polymorphic ventricular tachycardia with catecholamine infusion or exercise. Casq2-/- myocytes display premature spontaneous SR Ca2+ releases resulting in after- contractions and triggered beats. Significantly, commonly-used antidepressant drugs, which disrupt Ca2+ binding to CASQ2 in vitro, have also been linked to an increased incidence in sudden cardiac death, raising the possibility of a Casq2-linked form of drug-induced arrhythmias, analogous to the drug-associated long QT syndrome. Based on these human genetic, epidemiological, and mouse data, we hypothesize that disruption of Casq2 causes dysfunctional SR Ca2+ release and contributes to arrhythmia susceptibility and sudden death. To test our central hypothesis, we will examine single cell, whole heart and in vivo electrophysiology, contractile function, Ca2+ homeostasis, protein expression and SR ultrastructure in Casq2-/- , Casq2+/-, triadin-1 null (Trdn-/-) and selectively cross-bred animals. Our goals are to test the individual contribution of Casq2 and triadin-1 to arrhythmia susceptibility and further elucidate the molecular and cellular mechanism(s) that lead to ventricular arrhythmias in response to inherited and possibly drug-induced Casq2 dysfunction. The outcome of this research will not only advance our understanding of the pathophysiology of inherited arrhythmia syndromes, but also help unravel the mechanism(s) responsible for sudden deaths linked to antidepressant medications taken by millions of patients.
描述(由申请人提供):心脏钙螯合蛋白(CASQ 2)及其结合伴侣连接蛋白和三聚体蛋白-1(TRDN)是肌浆网(SR)钙储存和释放的关键调节因子。在人类中,CASQ 2突变导致儿茶酚胺能多态性室性心动过速和心源性猝死综合征。为了确定CASQ 2突变导致电生理不稳定但保留收缩功能的机制,我们产生了Casq 2 null(Casq 2-/-)小鼠。我们的初步研究表明,尽管缺乏Casq 2蛋白,这些小鼠仍保持接近正常的SR Ca 2+储存,这可能是由于SR体积的扩大和Casq 2结合蛋白triadin-1和junctin的急剧减少。Casq 2-/-小鼠通过用儿茶酚胺输注或运动发展多态性室性心动过速来表型复制人类CASQ 2相关的心律失常。Casq 2-/-肌细胞显示过早的自发性SR Ca 2+释放,导致后收缩和触发性搏动。值得注意的是,在体外破坏Ca 2+与CASQ 2结合的常用抗抑郁药物也与心源性猝死的发生率增加有关,这增加了Casq 2相关形式的药物诱导的心律失常的可能性,类似于药物相关的长QT综合征。基于这些人类遗传学、流行病学和小鼠数据,我们假设Casq 2的破坏导致SR Ca 2+释放功能障碍,并导致心律失常易感性和猝死。为了检验我们的中心假设,我们将在Casq 2-/-、Casq 2 +/-、三聚体蛋白-1缺失(Trdn-/-)和选择性杂交的动物中检查单细胞、整个心脏和体内电生理学、收缩功能、Ca 2+稳态、蛋白质表达和SR超微结构。我们的目标是测试Casq 2和三聚体-1对心律失常易感性的个体贡献,并进一步阐明导致室性心律失常的分子和细胞机制,以响应遗传和可能的药物诱导的Casq 2功能障碍。这项研究的结果不仅将促进我们对遗传性心律失常综合征病理生理学的了解,而且还有助于解开数百万患者服用抗抑郁药物导致猝死的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bjorn C Knollmann其他文献

Bjorn C Knollmann的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bjorn C Knollmann', 18)}}的其他基金

Toward a Mechanism-Based Approach to Treating Cardiac Arrhythmia
寻找基于机制的心律失常治疗方法
  • 批准号:
    10605187
  • 财政年份:
    2019
  • 资助金额:
    $ 44万
  • 项目类别:
Toward a Mechanism-Based Approach to Treating Cardiac Arrhythmia
寻找基于机制的心律失常治疗方法
  • 批准号:
    9888412
  • 财政年份:
    2019
  • 资助金额:
    $ 44万
  • 项目类别:
Toward a Mechanism-Based Approach to Treating Cardiac Arrhythmia
寻找基于机制的心律失常治疗方法
  • 批准号:
    10375446
  • 财政年份:
    2019
  • 资助金额:
    $ 44万
  • 项目类别:
Training Program in Ion Channel and Transporter Biology
离子通道和转运生物学培训计划
  • 批准号:
    9403769
  • 财政年份:
    2017
  • 资助金额:
    $ 44万
  • 项目类别:
Toward a Mechanism-Based Approach to Treating Atrial Fibrillation
寻找基于机制的心房颤动治疗方法
  • 批准号:
    9248413
  • 财政年份:
    2015
  • 资助金额:
    $ 44万
  • 项目类别:
Toward a Mechanism-Based Approach to Treating Atrial Fibrillation
寻找基于机制的心房颤动治疗方法
  • 批准号:
    9068340
  • 财政年份:
    2015
  • 资助金额:
    $ 44万
  • 项目类别:
Calsequestrin in Ventricular Arrhythmia and Sudden Death
Calsequestrin 治疗室性心律失常和猝死
  • 批准号:
    7251084
  • 财政年份:
    2007
  • 资助金额:
    $ 44万
  • 项目类别:
Calsequestrin in Ventricular Arrhythmia and Sudden Death
Calsequestrin 治疗室性心律失常和猝死
  • 批准号:
    7407567
  • 财政年份:
    2007
  • 资助金额:
    $ 44万
  • 项目类别:
Calsequestrin in Ventricular Arrhythmia and Sudden Death
Calsequestrin 治疗室性心律失常和猝死
  • 批准号:
    8245329
  • 财政年份:
    2007
  • 资助金额:
    $ 44万
  • 项目类别:
Calsequestrin in Ventricular Arrhythmia and Sudden Death
Calsequestrin 治疗室性心律失常和猝死
  • 批准号:
    7561247
  • 财政年份:
    2007
  • 资助金额:
    $ 44万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 44万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 44万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 44万
  • 项目类别:
    Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
  • 批准号:
    2889694
  • 财政年份:
    2023
  • 资助金额:
    $ 44万
  • 项目类别:
    Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 44万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 44万
  • 项目类别:
    Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 44万
  • 项目类别:
    Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 44万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 44万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了